WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME

The aim of the review is presenting the possibilities and perspectives of the third generation of thienopyridine P2Y12 receptor inhibitor prasugrel in the treatment of patients with acute coronary syndrome (ACS). The main pathogenetic stage of ACS is intracoronary thrombosis, which develops on the surface of a damaged atherosclerotic plaque. The use of acetylsalicylic acid with addition of the second antiplatelet agent, so-called dual antiplatelet therapy, is a standard component in the treatment of any type of ACS, regardless of reperfusion and the selected treatment strategy. Due to some limitations in the use of clopidogrel as the second component of dual antiplatelet therapy, the possibility of prasugrel or ticagrelor usage should be considered in patients with ACS with percutaneous coronary intervention (PCI). Prasugrel therapy is associated with better clinical outcomes as compared with clopidogrel therapy in moderate or high-risk patients who undergo PCI. Because of higher bleeding risk and the lack of clinical benefits in special subgroups of patients, prasugrel must not be used in patients with a stroke or transient ischemic attack in the past. If, after a thorough individual benefit-risk assessment a decision is in favor of prescribing prasugrel to the patient older than 75 years or with a small body weight the maintenance dose of prasugrel is to be reduced by half. Real clinical practice data has shown that with following these recommendations prasugrel demonstrates optimal efficacy, safety, and even more significant impact on the prognosis than this in clinical trials. Prasugrel is able to reduce significantly the incidence of cardiovascular events such as cardiovascular death, myocardial infarction and stroke in patients with ACS who undergo PCI.

1. Mozaffarian D., Benjamin E.J., Go A.S., et al. Heart disease and stroke statistics 2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29-322. doi: 10.1161/CIR.0000000000000152.

2. Demographic Yearbook of Russia (2015). Moscow: Rosstat; 2015. (In Russ.)

3. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451:914-8. doi: 10.1038/nature06797.

4. Le Breton H., Plow E.F., Topol E.J. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol. 1996;28(7):1643-51. doi: 10.1016/S0735-1097(96)00417-2.

5. Mehta S.R., Yusuf S. Shortand long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol. 2003;41(4 Suppl S):79S-88S. doi: 10.1016/S0735-1097(02)02831-0.

6. Chen Z.M., Jiang L.X., Chen Y.P. et al. Additon of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005;366:1607-21. doi: 10.1016/S0140-6736(05)67660-X.

7. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med. 2005;352:1179-89. doi: 10.1056/NEJMoa050522.

8. Yusuf S., Mehta S.R., Zhao F., et al., on Behalf of the CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) Trial Investigators. Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes. Circulation. 2003;107:966-72. doi: 10.1161/01.CIR.0000051362.96946.15.

9. Fitzgerald D.J., Maree A. Aspirin and clopidogrel resistance. Hematology. 2007:114-120. doi: 10.1182/asheducation-2007.1.114.

10. De Miguel A., Ibanez B., Badimon J.J. Clinical implications of clopidogrel resistance. Thromb Haemost. 2008;100:196-203.

11. Diagnosis and treatment of patients with acute myocardial infarction with ST segment elevation (part 1). Guidelines of the Society of Specialists in Emergency Cardiology. Emergency Cardiology. 2014;(1):42-62. (In Russ.)

12. Roffi M., Patrono C., Collet J.P., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315. doi: 10.1093/eurheartj/ehv320.

13. Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Societof Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi: 10.1093/eurheartj/ehx393.

14. Brandt J.T., Payne C.D., Wiviott S.D., et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(1):66. doi:10.1016/j.ahj.2006.10.010.

15. Asai F., Jakubowski J.A., Naganuma H., et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets. 2006;17(4):209-17. doi: 10.1080/09537100600565551.

16. Jakubowski J.A., Payne C.D., Brandt J.T., et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006;47(3):377-84. doi: 10.1097/01.fjc.0000210069.47205.c0.

17. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loadingand maintenancedose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923-32. doi: 10.1161/CIRCULATIONAHA.107.740324.

18. Wiviott S.D., Antman E.M., Gibson C.M., et al. Evaluation of Prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152(4):627-35. doi: 10.1016/j.ahj.2006.04.012.

19. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. doi: 10.1056/NEJMoa0706482.

20. Antman E.M., Wiviott S.D., Murphy S.A., et al. Early and late benefits of Prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with PrasugrelThrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008;51(21):2028-33. doi: 10.1016/j.jacc.2008.04.002.

21. Wiviott S.D., Braunwald E., McCabe C.H., et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITONTIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353-63. doi: 10.1016/S0140-6736(08)60422-5.

22. Wu T., Wang L. Angiographic characteristics of the coronary artery in patients with type 2 diabetes. Experimental & Clinical Cardiology. 2002;7(4):199-200.

23. GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J. 2001;141(2):190-9. doi: 10.1067/mhj.2001.112404.

24. Wiviott S.D., Braunwald E., Angiolillo D.J., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with Prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626-36. doi: 10.1161/CIRCULATIONAHA.108.791061.

25. Wiviott S., Antman E., Winters K., et al. Randomized comparison of Prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111:3366-73. doi: 10.1161/CIRCULATIONAHA.104.502815.

26. Murphy S.A., Antman E.M., Wiviott S.D., et al. Reduction in recurrent cardiovascular events with Prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008;29(20):2473-2479. doi: 10.1093/eurheartj/ehn362.

27. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57. doi: 10.1056/NEJMoa0904327.

28. Montalescot G., Wiviott S.D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723-31. doi: 10.1016/S01406736(09)60441-4.

29. Husted S, Boersma E. Case study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGYACS trials in patients with acute coronary syndromes. Am J Ther. 2016;23:e1876-89. doi:10.1097/MJT.0000000000000237.

30. Khan N., Cox A.R., Cotton J.M. Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review. Tromb Res. 2016;143:1418. doi: 10.1016/j.thromres.2016.05.019.

31. Angiolillo D.J., Curzen N., Gurbel P., et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 study (switching anti platelet-2). J Am Coll Cardiol. 2014;63:1500-9. doi: 10.1016/j.jacc.2013.11.032.

32. Motovska Z., Hlinomaz O., Miklik R., et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation. 2016;134:1603-12. doi: 10.1161/CIRCULATIONAHA.116.024823.

33. Olier I., Sirker A., Hildick-Smith D.J.R., et al. Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention. Heart. 2018 Feb 2. pii: heartjnl-2017312366. doi: 10.1136/heartjnl-2017-312366.

34. Khayata M., Gabra J.N., Nasser M.F., et al. Comparison of Clopidogrel With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndrome: Clinical Outcomes From the National Cardiovascular Database ACTION Registry. Cardiol Res. 2017;8(3):105-10. doi: 10.14740/cr560w.

35. Valgimigli M., Bueno H., Byrne R.A. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for CardioThoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.